Exchange
SSE
Every company in the roster listed on SSE.
Research
Compare financial metrics on this exchange
Research adds market cap, cash, runway and annualized R&D metrics with metric-specific sorting.
Views
12 of 12 companies
| Company | Pipeline | Most advanced | Next readout |
|---|---|---|---|
 Jiangsu Hengrui Pharmaceuticals600276 · SSE | 56 assets: 27 Ph 3, 16 Ph 2, 13 Ph 1 | ApatinibPhase 3 · Non-Small Cell Lung CancerReliable signal | 30 Oct 2026HRS-6209 · Phase 1/2 |
 RemeGen Co., Ltd.688331 · SSE | 6 assets: 4 Ph 3, 1 Ph 2, 1 Ph 1 | TelitaciceptPhase 3 · Systemic Lupus ErythematosusReliable signal | Dec 2026Disitamab Vedotin · Phase 2/3 |
 Chipscreen Biosciences688321 · SSE | 4 assets: 2 Ph 3, 1 Ph 2, 1 Ph 1 | ChiglitazarPhase 3 · Type 2 DiabetesReliable signal | 26 Oct 2026Chiglitazar · Phase 1 |
 Gan & Lee Pharmaceuticals603087 · SSE | 4 assets: 2 Ph 3, 2 Ph 2 | GZR18Phase 3 · ObesityPartial signal | 11 Dec 2026GZR18 · Phase 3 |
 Tasly Pharmaceutical Group600535 · SSE | 4 assets: 4 Ph 2 | QiShenYiQiPhase 2 · Heart FailurePartial signal | 31 Dec 2026Jia Shen Tablet · Phase 2 |
 Sinocelltech Group Ltd.688520 · SSE | 3 assets: 3 Ph 3 | SCTB14Phase 3 · Non-Small Cell Lung Cancer | Apr 2027SCTC21C · Phase 1/2 |
 BrightGene Bio-Medical Technology688166 · SSE | 2 assets: 1 Ph 3, 1 Ph 1 | BGM0504Phase 3 · ObesityPartial signal | 28 Feb 2027BGM0504 · Phase 2 |
Shanghai Pharmaceuticals Holding2607 · SSE | 2 assets: 2 Ph 3 | sitokirenPhase 3 · HypertensionPartial signal | 1 Dec 2026SPH4336 · Phase 2/3 |
Tonghua Dongbao Pharmaceutical600867 · SSE | 2 assets: 1 Ph 3, 1 Ph 2 | THDB0206Phase 3 · Type 2 DiabetesPartial signal | None on record |
 Xiamen Amoytop Biotech Co., Ltd.688278 · SSE | 1 asset: 1 Ph 1 | ACT201 InjectionPhase 1 · Chronic Hepatitis B | Mar 2027ACT201 Injection · Phase 1 |
 Zhejiang Hisun Pharmaceutical600267 · SSE | 1 asset: 1 Ph 3 | HyzetimibePhase 3 · Atherosclerotic Cardiovascular DiseasePartial signal | None on record |
 Zhejiang Huahai Pharmaceutical600521 · SSE | 1 asset: 1 Ph 2 | Hypidone (YL-0919)Phase 2 · Major Depressive DisorderPartial signal | None on record |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov).